SCHEMBL3876478

SCHEMBL3876478

CC(=O)CC(C(=O)O)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.54
CYP2C19 P33261 1/20 0.53
POLB P06746 2/20 0.53
ALDH1A1 P00352 3/20 0.49
GAA P10253 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
CYP2D6 P10635 1/20 0.46
SRC P12931 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46
LMNA P02545 2/20 0.45
MAPK1 P28482 1/20 0.45
EPHX1 P07099 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12294610 1.00 SMN1; SMN2 (0.54) SMN1; SMN2CYP2C19POLBALDH1A1GAA
SCHEMBL12294613 1.00 SMN1; SMN2 (0.54) SMN1; SMN2CYP2C19POLBALDH1A1GAA
SCHEMBL2915594 0.88 ALDH1A1 (0.46) SMN1; SMN2CYP2C19POLBALDH1A1L3MBTL1
SCHEMBL2915242 0.88 ALDH1A1 (0.46) SMN1; SMN2CYP2C19POLBALDH1A1L3MBTL1
SCHEMBL1977280 0.88 ALDH1A1 (0.46) SMN1; SMN2CYP2C19POLBALDH1A1L3MBTL1
SCHEMBL12718845 0.84 EPHX1 (0.59) SMN1; SMN2CYP2C19ALDH1A1CYP2D6KDM4E
SCHEMBL27607399 0.84 POLB (0.59) SMN1; SMN2CYP2C19POLBALDH1A1GAA
SCHEMBL6468998 0.84 SMN1; SMN2 (0.51) SMN1; SMN2CYP2C19POLBALDH1A1GAA
SCHEMBL9118493 0.84 KDM4E (0.47) SMN1; SMN2CYP2C19POLBALDH1A1L3MBTL1
SCHEMBL377609 0.83 L3MBTL1 (0.61) SMN1; SMN2CYP2C19POLBALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101260532-A One-room type electrochemical synthesis method for alpha-phenylacetpropionic acid UNIV EAST CHINA NORMAL (CN) 2008-09-10 CN claimed
CN-114058237-B Corrosion resistant coating composition 中国涂料株式会社 2023-12-26 CN disclosed
CN-116981743-A Corrosion protection composition 1 and corrosion protection coating composition 中国涂料株式会社 2023-10-31 CN disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
CN-113413456-A Method for producing recombinant peptides and resulting peptides OVB(爱尔兰)有限公司 2021-09-21 CN disclosed
CN-104662034-B Method for producing recombinant peptides and resulting peptides "IVIX"有限公司 2021-05-11 CN disclosed
US-9796705-B2 Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases MERCK SHARP & DOHME CORP. (US) 2017-10-24 US disclosed
US-20170158735-A1 METHOD FOR PRODUCING A RECOMBINANT PEPTIDE AND RESULTANT PEPTIDE "IVIX" LTD. (RU) 2017-06-08 US disclosed
US-20170008879-A1 FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME CORP. (US) 2017-01-12 US disclosed
CN-106305714-A Fruit fly attractant concentrated solution and matched fruit fly attractant thereof 尹正平 2017-01-11 CN disclosed
US-20020081675-A1 Microbial process for preparing pravastatin JEKKEL ANTONIA (HU) 2002-06-27 US disclosed
US-20020022637-A1 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues BRISTOL-MYERS SQUIBB COMPANY 2002-02-21 US disclosed
EP-1154979-A1 MICROBIAL PROCESS FOR PREPARING PRAVASTATIN Institute for Drug Research Ltd. (HU) 2001-11-21 EP disclosed
WO-2001085695-A1 TETRAHYDROISOQUINOLINE ANALOGS USEFUL AS GROWTH HORMONE SECRETAGOGUES BRISTOL-MYERS SQUIBB CO. (US) 2001-11-15 WO disclosed
US-6261811-B1 FUNGI IMMOBILIZED INTO OR ONTO LOOFAH SPONGE ; ACCELERATED PRODUCTION OF COMPOUNDS SUCH AS COMPACTIN UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. 2001-07-17 US disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 EP disclosed
WO-2000046175-A1 MICROBIAL PROCESS FOR PREPARING PRAVASTATIN INSTITUTE FOR DRUG RESEARCH LTD. (HU) 2000-08-10 WO disclosed
WO-2000037665-A1 METHOD AND SYSTEM FOR THE CONTINUOUS SYNTHESIS OF NATURAL PRODUCTS USING IMMOBILIZED FUNGAL SPORES THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) 2000-06-29 WO disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 WO disclosed
US-4279918-A ANTIDEPRESSANTS, STIMULANTS BYK GULDEN LOMBERG CHEMISCHE FABRIK G.M.B.H. (DE) 1981-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170008879-A1 FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES ZC3HAV1, HAVCR2, ZC3HAV1L SMN1; SMN2 957/4885CYP2C19 2096/4885POLB 801/4885
US-20020022637-A1 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues GHSR, GHRHR, MSTN SMN1; SMN2 846/4885CYP2C19 4234/4885POLB 4093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.